Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients - Wikidata - wikimedia - TriplyDB

Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients

Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients

http://www.wikidata.org/entity/Q36613622

about

Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.Long-term platinum retention after treatment with cisplatin and oxaliplatin.Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients.Effects of Genetic Polymorphisms of Glutathione S-transferase P1 on Helicobacter pylori-associated Gastric Cancer.Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.Sinomenine sensitizes gastric cancer cells to 5-fluorouracil in vitro and in vivo Translational medicine and reliability of single-nucleotide polymorphism studies: can we believe in SNP reports or not?SOD2 rs4880 CT/CC genotype predicts poor survival for Chinese gastric cancer patients received platinum and fluorouracil based adjuvant chemotherapy.Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus Polymorphism in one-carbon metabolism pathway affects survival of gastric cancer patients: Large and comprehensive study Glutathione S-Transferase Gene Polymorphisms and Treatment Outcome in Cervical Cancer Patients under Concomitant Chemoradiation.GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy.Clinical implications of genetic polymorphisms on stomach cancer drug therapy.GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.Can GSTM1 and GSTT1 polymorphisms predict clinical outcomes of chemotherapy in gastric and colorectal cancers? A result based on the previous reports.Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.Expression of thymidylate synthase and glutathione-s-transferase pi in patients with esophageal squamous cell carcinoma.Prognostic Significance and Clinicopathological Associations of COX-2 SNP in Patients with Nonsmall Cell Lung Cancer A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer p A bioactive probe for glutathione-dependent antioxidant capacity in breast cancer patients: implications in measuring biological effects of arsenic compounds.Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients.Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.Gastric cancer pharmacogenetics: progress or old tripe?Capecitabine in the treatment of esophageal and gastric cancers.Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death.Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?Predictive genetic markers in neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: a long way to go. Review of the literature.Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis.Pharmacogenetics and stomach cancer: an update.Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.Is thymidylate synthase a reliable predictor for response and survival during hepatic arterial infusion for hepatic metastases from colorectal cancer?A pilot study to investigate the role of thymidylate synthase as a marker of prognosis for neoadjuvant chemotherapy in gastric and gastro-oesophageal junction adenocarcinoma.Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.A functional polymorphism of SSBP1 gene predicts prognosis and response to chemotherapy in resected gastric cancer patients.Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.

P2860

Q26824719-848CEC79-E37C-4CE5-A254-2A18BFFF1C03 Q33337970-7B48F533-06ED-43EA-82F2-51EBCE681005 Q33369988-D4959202-F1D5-40F9-9021-5E5E96B14E98 Q33816134-2D1A20AD-34E1-49B1-8D01-1518C0BA0218 Q33855577-7FA1EBD9-C329-43A3-9190-1EC52ECCF23D Q33879736-F4FBD7C7-8A24-4260-9530-CCFFB004BDEC Q35048000-61A76E06-CD9D-4B66-BDFE-FF51508278D5 Q35196724-AF7DC132-59DA-44F6-BFF1-29FCEE18312A Q35440258-16AFB952-DC64-4968-A5BD-36AA42E1C4CE Q35584647-0A21CA28-22F0-462D-92E6-E07D0A67FEE7 Q35827846-F5FDE97F-EC3F-4261-8B80-17D478A04C9A Q35832445-5570A63F-4644-4A5A-8D8C-78538BFB227C Q35842082-8F6C0370-ECEF-44FB-AD91-131E513AA8AA Q36044627-027C0104-AEDE-4263-9BAC-FDAF33FAA892 Q36519876-EBE1A2CC-FBA7-4567-8AC5-8D8E921F0C82 Q36943992-0DB60043-E24F-45D6-AE5B-0998A3A66B0E Q37042575-110DBA6B-C1F8-4381-8206-B3010522EDEF Q37284259-BD4F5431-4B06-4229-B1F4-5AE78D0F22B2 Q37347351-6879C266-2D60-4B48-B3A1-24DE322AA7D9 Q37475804-4B5E7A5E-A65F-4349-884C-C051F1633EEB Q37580616-3517F688-C4D2-4B3E-85D0-FAC16A8062D9 Q37625524-D6D65AFC-4C5A-4AA3-9901-7EB5A8F7ACEB Q37657540-8C369EE7-E1DA-476C-9F61-EFE4AAF7D6E1 Q37688251-4A0E804F-8DA3-41E4-8748-6AC7D82AE937 Q37887337-108FFF7E-CAE9-453E-A012-354797E0FB79 Q38120288-49DDA21A-98B1-43CA-8FD9-B686BBA44616 Q38148794-F225D231-F67B-4BDE-A092-5A688046102A Q38241806-4476F73C-B4B2-4278-A8EB-399C37526DB0 Q38276429-3107DD59-491F-4A10-BC22-63B18B7EB40E Q38728693-66D58A56-07A2-480E-8222-86C4DB459E8B Q38827826-532AB4F6-43AF-41F6-94AA-ABDEF57153CA Q40218486-93E3E576-577C-4D3E-B04B-805C31E741E0 Q41187621-C26CAB76-D20F-4796-A07E-F1A8A78F4BEB Q41442402-B2719303-A007-4DD7-85FD-493C08488C92 Q42727098-D5F42C14-5409-4664-BB8C-0DD2F6FF445F Q43199518-8FF7E2FD-DDBD-45CE-98D6-CF8C58E5C401 Q43223220-2EE15933-45BC-49E0-9616-FDCD406C28AA Q47876292-8E3C2AF9-9F73-4F37-A7D6-E93A22FC8A7D Q49991976-609A422E-BBE3-4A19-85DA-1769456A86E8 Q53621686-95F56DA3-549E-4DA4-9408-A71ACBB3436F

P2860

Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients

http://www.wikidata.org/entity/Q36613622

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Polymorphisms of glutathione S ...... val in gastric cancer patients

@ast

Polymorphisms of glutathione S ...... val in gastric cancer patients

@en

type

label

Polymorphisms of glutathione S ...... val in gastric cancer patients

@ast

Polymorphisms of glutathione S ...... val in gastric cancer patients

@en

prefLabel

Polymorphisms of glutathione S ...... val in gastric cancer patients

@ast

Polymorphisms of glutathione S ...... val in gastric cancer patients

@en

P1433

Q36613622-130279C1-E2A6-4A91-86DF-24BAE501AAF5

P1476

Q36613622-5032EF66-BC22-4044-9861-E3D67F83465A

P2093

Q36613622-1C656CCC-A1FD-4EAE-8CC6-461E7D293F9C

Q36613622-27E5B6C2-2C0E-4749-8326-2D0565BD3AAA

Q36613622-322BA2C0-6738-41E2-8B3C-1D9D28A37E82

Q36613622-5E78959D-15C7-49FE-BD2C-724CE8DC02D1

Q36613622-6EC0250E-EB39-427E-8384-ED011AAFAA0D

Q36613622-82D3EF4A-9A06-4A3F-961B-C74AAFB16CC9

Q36613622-94423D07-CCBE-4B07-899D-ADE5359DD64F

P2860

Q36613622-11520793-37EA-47A2-B130-396E11037F21

Q36613622-1195ED1F-DCFC-4D72-87FF-D64D7F39EB0D

Q36613622-22D5D51F-84A7-4C9B-9A73-3370A2E18DEB

Q36613622-2D5E9023-FE3E-41A2-ADA4-A69E9F55C6B0

Q36613622-31D53122-13D3-45C0-A25A-F731A1298087

Q36613622-3D272F48-5D42-4942-93D1-E1B5801DF7F7

Q36613622-498A5510-E0F5-47B2-80CE-9FCD85DCDF47

Q36613622-5447C951-9135-4B92-A865-8EDAD173E6D1

Q36613622-5BDED90E-4577-4A12-B71C-90C17D021583

Q36613622-665F2BBF-610C-423F-A50A-5C6962EAFFE4

P2888

Q36613622-60FC9A8E-3A7E-449A-83B2-73F43EA758D0

P304

Q36613622-152E221A-513F-49AC-B644-C4281C080E93

P31

Q36613622-57CC3B53-2F88-408D-9BBC-34C15D249491

P356

Q36613622-02FE2EAC-0F11-4505-9E3B-58B347E8AE38

P407

Q36613622-34924F75-83F4-47B4-9379-185A1B80B03B

P433

Q36613622-C929F29C-959D-408F-BF6A-FC0409CE6A83

P478

Q36613622-7477AF1D-6DC0-4AD4-AC2E-F3CA908CCA14

P577

Q36613622-3133A523-10AD-4249-AB3F-69B87F493F82

P5875

Q36613622-0300247F-EC87-4668-AED4-1F80D62E26DC

P6179

Q36613622-1AC2C375-4A37-40BE-8C6C-E431161AA321

P698

Q36613622-1F8A9EE7-7481-485E-94A3-34E757C713E0

P932

Q36613622-4DC23BCD-711B-4685-BE5C-84A8B7268C49

P356

P1433

British Journal of Cancer

P1476

Polymorphisms of glutathione S ...... val in gastric cancer patients

@en

P2093

Goekkurt E

http://www.w3.org/2001/XMLSchema#string

Hoehn S

http://www.w3.org/2001/XMLSchema#string

Hossfeld DK

http://www.w3.org/2001/XMLSchema#string

Stoehlmacher J

http://www.w3.org/2001/XMLSchema#string

Stueber C

http://www.w3.org/2001/XMLSchema#string

Wittmer C

http://www.w3.org/2001/XMLSchema#string

Wolschke C

http://www.w3.org/2001/XMLSchema#string

P2860

A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism

Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans

A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.

Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.

Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.

Global cancer statistics in the year 2000.

Thymidylate synthetase - a target enzyme in cancer chemotherapy.

The treatment of advanced gastric cancer: new findings on the activity of the taxanes.

P2888

P304

281-286

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6602891

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7452432

http://www.w3.org/2001/XMLSchema#string

P6179

1012080567

http://www.w3.org/2001/XMLSchema#string

P698

16317430

http://www.w3.org/2001/XMLSchema#string

P932

2361118

http://www.w3.org/2001/XMLSchema#string